Shots:

• The P-II/III study will assess the safety & efficacy Kevzara + supportive care vs PBO + supportive care in ~400 patients in a ratio (2:2:1) hospitalized with serious complications from COVID-19
• The study is designed into two parts:  First part will evaluate the impact of Kevzara on fever and patients' need for supplemental oxygen while the second part will evaluate the improvement in longer-term outcomes including preventing death & reducing the need for mechanical ventilation- supplemental oxygen and/or hospitalization
• Kevzara is a mAb inhibiting IL-6 pathway by targeting the IL-6 receptor. The companies will continue to collaborate on COVID-19 and other ARDS development- with Regeneron leading US studies and Sanofi leading ex-US studies. In 2019- the companies intend to simplify the joint collaboration for Kevzara- which is expected to be finalized in the Q1’20

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Pharmaceutical Technolog